Zobrazeno 1 - 10
of 80
pro vyhledávání: '"Thomas Ryll"'
Autor:
Renpeng Liu, Lintao Wang, Thomas Ryll, Alexandru C. Lazar, Xuan Chen, Megan Bogalhas, Junia Dushime
Publikováno v:
mAbs. 9:490-497
Antibody-drug conjugates (ADCs) are promising biotherapeutic agents for the treatment of cancer. The careful monitoring of critical quality attributes is important for ADCs' development, manufacturing and production. In this work, the effect of the p
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b81677ee96b973f0b253fc466d84d653
https://doi.org/10.1080/19420862.2017.1285478
https://doi.org/10.1080/19420862.2017.1285478
Autor:
Kelly Wiltberger, Rebecca C. Timson, Rashmi Kshirsagar, Terrence M. Dobrowsky, Brandon Berry, Thomas Ryll
Publikováno v:
Biotechnology Progress. 32:224-234
Mitigating risks to biotherapeutic protein production processes and products has driven the development of targeted process analytical technology (PAT); however implementing PAT during development without significantly increasing program timelines ca
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::eaaee077fdd035cce7e0788378ab07f7
https://doi.org/10.1002/btpr.2205
https://doi.org/10.1002/btpr.2205
Autor:
Lam Raga Anggara Markely, Lila Cheung, Young Jun Choi, Thomas Ryll, Scott Estes, Shashi Prajapati, Iva Turyan, Ruth Frenkel, Zoran Sosic, James Lambropoulos, Lia Tescione, Melissa Berman
Publikováno v:
Biotechnology Progress. 32:235-241
The serum half-life, biological activity, and solubility of many recombinant glycoproteins depend on their sialylation. Monitoring glycoprotein sialylation during cell culture manufacturing is, therefore, critical to ensure product efficacy and safet
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a7e7c34931861fd97ec8d28366fdb2d3
https://doi.org/10.1002/btpr.2206
https://doi.org/10.1002/btpr.2206
Autor:
Kristina Ladd, Seth Kitchener, Sven Loebrich, Robert Herbst, Stefani Takahashi, Anna Brousseau, Thomas Ryll, Elisa Clark
Publikováno v:
mAbs. 11(2)
The extent and pattern of glycosylation on therapeutic antibodies can influence their circulatory half-life, engagement of effector functions, and immunogenicity, with direct consequences to efficacy and patient safety. Hence, controlling glycosylati
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::52aad89b67f4f8bdc69bfd52e843bed3
https://pubmed.ncbi.nlm.nih.gov/30252592
https://pubmed.ncbi.nlm.nih.gov/30252592
Autor:
Anna Evans, Henning Galinski, Thomas Ryll, Jennifer L. M. Rupp, René Tölke, Anja Bieberle-Hütter, Barbara Scherrer, Ludwig J. Gauckler
Publikováno v:
Monatshefte für Chemie, 140 (9)
Monatshefte für Chemie, 140 (9)
ISSN:0026-9247
ISSN:1434-4475
ISSN:0026-9247
ISSN:1434-4475
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::01a152cd8c8274ee998a8c4ca0e4bdbe
http://doc.rero.ch/record/316943/files/706_2009_Article_107.pdf
http://doc.rero.ch/record/316943/files/706_2009_Article_107.pdf
Autor:
Rashmi, Kshirsagar, Thomas, Ryll
Publikováno v:
Advances in biochemical engineering/biotechnology. 165
Cell culture-based production processes enable the development and commercial supply of recombinant protein products. Such processes consist of the following elements: thaw and initiation of culture, seed expansion, and production culture. A robust c
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::ec2223925774a5b240d2f8f5087a934f
https://pubmed.ncbi.nlm.nih.gov/29637222
https://pubmed.ncbi.nlm.nih.gov/29637222
Autor:
Rashmi Kshirsagar, Thomas Ryll
Publikováno v:
New Bioprocessing Strategies: Development and Manufacturing of Recombinant Antibodies and Proteins ISBN: 9783319971087
Cell culture-based production processes enable the development and commercial supply of recombinant protein products. Such processes consist of the following elements: thaw and initiation of culture, seed expansion, and production culture. A robust c
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::4ccaa1026d10648019e97b0d6158cb78
https://doi.org/10.1007/10_2016_56
https://doi.org/10.1007/10_2016_56
Autor:
Rashmi Kshirsagar, Lynn Conley, Yao-Ming Huang, Edward Koepf, Thomas Ryll, Doug Cecchini, Sethu Siva, An Zhang
Publikováno v:
Engineering in Life Sciences. 16:143-151
Acceleration of development timelines to support material production for early-phase clinical trials has been a continuous goal within the life sciences industry, driven largely by the need to advance an ever increasing number of novel therapeutics i
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::9e218b28075b8056cff8fa1aa5552c2e
https://doi.org/10.1002/elsc.201500028
https://doi.org/10.1002/elsc.201500028
Autor:
Rashmi Kshirsagar, Thomas Ryll, Vivian Shen, Yao-ming Huang, Valerie Liu Tsang, Brandon Moore, An Zhang
Publikováno v:
Biotechnology and Bioengineering. 112:2495-2504
It is a common practice in biotherapeutic manufacturing to define a fixed-volume feed strategy for nutrient feeds, based on historical cell demand. However, once the feed volumes are defined, they are inflexible to batch-to-batch variations in cell g
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::230bf650a9011c8088f69c66e459e683
https://doi.org/10.1002/bit.25684
https://doi.org/10.1002/bit.25684
Publikováno v:
Pharmaceutical Bioprocessing. 2:519-534
Critical to the biopharmaceutical industrial objectives are robust, reproducible processes which result in consistent product quality and yields. These parameters support the product safety and efficacy as well as control over the process and supply
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::73e705db4a02b6282208ebe78354f304
https://doi.org/10.4155/pbp.14.35
https://doi.org/10.4155/pbp.14.35